Abstract 2579
Background
NSR-SCC is a rare subset of bladder tumors distinct from urothelial carcinoma (UC). Most studies that have assessed molecular biomarkers in bladder cancer have been limited to UC. We aim to characterize the genomic profile of NSR-SCC and to correlate genomic alterations with survival outcomes.
Methods
This was a retrospective study of NSR-SCC patients (pts) at Princess Margaret Cancer Centre. Patient demographics, risk factors, disease characteristics, treatment modalities, and survival outcomes were collected for eligible pts. Genomic DNA and complementary DNA were analyzed using Oncomine® V3 assay, a targeted NGS platform. Overall survival (OS) was estimated by Kaplan-Meier (log-rank). Uni- (UVA) and multi-variate (MVA) analysis (Cox-regression) was used to evaluate the impact of patient and genomic characteristics on OS.
Results
We identified 11 pts with NSR-SCC from 2002-2017, with median age 71 years (range 46-86) and 7 were male. Nine pts had muscle invasive, 1 superficial stage and 1 distant metastasis. Nine pts had radical cystectomy and LN dissection. Eight pts had pT3 or pT4 with N0 and 6 were grade 2. Median OS was 12.5 months (95 % CI 7.7- 17.2 months). Common point mutations were identified in TERT (73%), TP53 (73%), PIK3CA (27%), CREBBP (18%), FBXW7 (18%), and PTEN (18%). Amplifications were identified in EGFR (18%), FGF3 (18%), CCND1 (18%), and FGF19 (18%). Additional mutations were detected at a frequency <10%. On UVA, only bladder irritants (e.g. prior radiation, urinary catheter, infection) were associated with improved OS (HR = 0.091; p = 0.031). A limited MVA didn’t identify any significant prognostic genomic abnormalities: TP53 (HR = 2.2; 95%CI: 0.3-17; p = 0.425), TERT (HR = 1.45; 95%CI: 0.2-10.2; p = 0.70) and PIK3CA (HR = 0.46; 95%CI: 0.1- 2.0; p = 0.31).
Conclusions
In this NSR-SCC series, we identified a number of actionable genomic alterations that may be targeted with drugs. No mutation was able to define different prognostic groups. Many of these aberrations were seen in UC. Biomarker driven studies in UC should consider enrollment of NSR-SCC pts who harbor these putative mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aaron Hansen.
Funding
Astellas.
Disclosure
A.G. Sacher: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self): Merck; Honoraria (self): Genentech-Roche. G. Kulkarni: Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy: Sanofi. A. Zlotta: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Ferring; Advisory / Consultancy: Janssen. A.R. Hansen: Advisory / Consultancy, Research grant / Funding (self): Genentech; Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): GSK; Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers; Advisory / Consultancy, Research grant / Funding (self): Squibb; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract